Summit Therapeutics (SMMT) Remains an Under-the-Radar DMD Play to Watch - Oppenheimer

December 18, 2015 12:57 PM

Oppenheimer analyst Christopher Marai reiterated an Outperform rating and $28 price target on Summit Therapeutics plc (NASDAQ: SMMT), saying the ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found